Videos

Treatment of NSCLC With Uncommon EGFR Mutations

Tanios Bekaii-Saab, MD, professor of medicine at the Mayo Clinic, discusses results of the ReDOS trial. In the trial, investigators compared 2 arms with different dosing strategies for regorafenib in patients with metastatic colorectal cancer.

Treatment of Relapsed Follicular Lymphoma with High Risk Status

Jason J. Luke, MD, assistant professor of medicine at the The University of Chicago Medicine, discusses the importance of conducting research into less common subsets of melanoma. After giving a talk on non-cutaneous melanoma, a rare subtype, Luke explained that not all cases of melanoma arise on the skin and shared why more research is necessary in the field.

Rodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Alessandro D. Santin, MD, a professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses results of a randomized phase II trial of trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab (Herceptin) in advanced or recurrent uterine serous carcinomas that overexpress HER2/neu during the 2018 Society of Gynecologic Oncology Annual Meeting.

Mark S. Soberman, MD, MBA, FACS, 2017-2018 president of the Association of Community Cancer Centers (ACCC), discusses various approaches that can be used to integrate multidisciplinary healthcare programs into various healthcare settings, following a panel discussion during the ACCC 44th Annual Meeting & Cancer Center Business Summit.

Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.

Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma. With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.

Frederick Locke, MD, co-leader of the Department of Blood and Marrow Transplant and Cellular Immunotherapy Program at Moffitt Cancer Center, discussed the long-term follow-up results of the pivotal ZUMA-1 trial. These updated findings were presented at the 2017 ASH Annual Meeting, showing promise in the treatment of patients with non-Hodgkin lymphoma.

Kidney Cancer

Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer. 

Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable.